Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
Coadministering COVID-19, influenza, and PPSV23 vaccines seems feasible, without significantly impairing neutralizing antibody responses. These findings support the recommendation for vaccine coadministration in adults.
Authors
- Omid Rezahosseini (ORCID: https://orcid.org/0000-0003-2198-1904)
- Zitta Barrella Harboe (ORCID: https://orcid.org/0000-0001-5552-0095)
- Jens‐Ulrik Stæhr Jensen (ORCID: https://orcid.org/0000-0003-4036-0521)
- Sisse Rye Ostrowski (ORCID: https://orcid.org/0000-0001-5288-3851)
- Thea Kølsen Fischer (ORCID: https://orcid.org/0000-0003-4812-980X)
- Charlotte Sværke Jørgensen (ORCID: https://orcid.org/0000-0002-7156-1986)
- Jens Dilling Lundgren (ORCID: https://orcid.org/0000-0001-8901-7850)
- Hassan Rahimi
- Lars Østergaard (ORCID: https://orcid.org/0000-0003-2459-0511)
- Ν. E. Jensen
Institutions
- Statens Serum Institut (DK)
- University of Copenhagen (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
- Centre of Excellence for Health, Immunity and Infections (DK)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1093/cid/ciaf455
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00